Knowledge Centre

Licensee Case Study: Bioneer

Making CRISPR more accessible for scientific innovation   At ERS Genomics, we make CRISPR/Cas9 accessible to innovators. By licensing the foundational IP co-owned by Professor…

Annual Letter From The CEO

Dear Stakeholders, As we step into 2025, I’d like to take a moment to reflect on the remarkable progress we’ve made in the CRISPR landscape…

A Letter from the CEO

  ERS Genomics stands as the global leader in CRISPR/Cas9 licensing, uniquely positioned at the intersection of cutting-edge science, commercial accessibility, and responsible innovation. Our…